FDA Brief

Warning letters Drugs

FDA warning letter to

Silgan Dispensing Systems

High riskIssued Oct 5Posted Oct 13Center for Drug Evaluation and Research (CDER)

Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

What happened

FDA inspected Silgan Unicep Packaging's drug manufacturing facility in Spokane, Washington, from March 26 to April 2, 2026. FDA found the firm invalidated out-of-specification (OOS) microbiological results by averaging yeast and mold counts to get passing results and then released affected lots; a customer later began a Class I recall because of potential fungal contamination. FDA also reviewed product labeling and a website in July 2026 and found products promoted as drugs without approved applications.

What FDA found

  1. The firm failed to thoroughly investigate out-of-specification (OOS) microbiological results and instead averaged yeast and mold counts to obtain passing results, contrary to USP <61>, before releasing affected lots.

    21 CFR 211.192
  2. The firm's investigation of potential fungal contamination was inadequate: corrective actions were ineffective, the line lacked cleaning validation, and environmental monitoring did not include yeast and mold testing.

    21 CFR 211.192
  3. The quality unit failed to validate supplier test analyses at appropriate intervals, follow a written stability testing program, and maintain records for annual product quality reviews.

    21 CFR 211.22; 21 CFR 211.84(d)(2); 21 CFR 211.166(a); 21 CFR 211.180(e)
  4. The firm's labeling and website presented products as drugs, but they are unapproved new drugs because they are not generally recognized as safe and effective and no approved application is in effect.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA tells the firm to respond in writing within 15 business days with independent reviews, remediation plans, risk assessments, complete investigations, and retain-sample testing, and to notify FDA before resuming drug manufacturing. FDA also says to engage a qualified consultant for a six-system audit before seeking resolution of its compliance status.

Who should pay attention

  • brands that buy OTC drug products from contract manufacturers
  • drugmakers using Silgan Unicep as a contract manufacturer
  • quality teams managing supplier microbial contamination and recalls

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk